ORPHA:90053
Complications after hematopoietic stem cell transplantation
Also known as: Complications after HSCT
Publications
565
Trials
0
Interventional, condition-specific
Researchers
1,344
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
565 matched papers (358 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
565
565 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
565 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
358 in the last 10 years · low confidence
Phrase hits: 565 · MeSH hits: 0
Who's working on it?
1,344
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Date H9 papers · 2025
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Papers in Europe PMC - 02Wang L6 papers · 2026
Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 03Myers KC5 papers · 2025
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio.
Papers in Europe PMC - 04Zhang J5 papers · 2025
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medical, Hangzhou, China.
Papers in Europe PMC - 05Zhang X5 papers · 2026
Department of Hematology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Papers in Europe PMC - 06Chen-Yoshikawa TF4 papers · 2022
Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.
Papers in Europe PMC - 07Davies SM4 papers · 2025
Cincinnati Children's Hospital Medical Center Cincinnati, Ohio.
Papers in Europe PMC - 08Huang X4 papers · 2026
Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China.
Papers in Europe PMC - 09Liu Y4 papers · 2025
Department of Hematology, Peking University First Hospital, Beijing, China.
Papers in Europe PMC - 10Xu L4 papers · 2026
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medical, Hangzhou, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 18 · after dedupe 18 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 18 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (18)
- isrctn·ISRCTN79300015·No longer recruiting·A study of JNJ-88549968 for the treatment of calreticulin (CALR)-mutated myeloproliferative neoplasms
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12632431·Recruiting·A Phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27200385·No longer recruiting·A study to assess the safety and distribution of GDC-8264 in combination with standard of care corticosteroid treatment in the blood of participants with high-risk acute graft-versus-host disease (aGVHD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15110275·No longer recruiting·Cell therapy clinical trial of BOXR1030 in GPC3 positive liver, squamous lung, Merkel cell cancer, and myxoid/round cell liposarcoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15021247·No longer recruiting·Phase II study for the treatment of recurrent and/or metastatic human papillomavirus (HPV16)-associated head and neck cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15323014·Recruiting·CAR T cells to fight T cell leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN54428419·No longer recruiting·Haploidentical stem cell transplantation for paediatric patients with thalassemia major
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13301994·No longer recruiting·Using nitrogen-washout to detect lung disease after donor-stem cell transplantation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22322271·No longer recruiting·Adenovirus Specific Paediatric Immune Reconstitution
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN39133198·No longer recruiting·Autologous Stem cell Transplantation International Crohn's disease trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27226314·No longer recruiting·Safety and efficacy of human lactoferrin hLF1-11 for the treatment of infectious complications among haematopoietic stem cell transplant recipients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89448306·Recruiting·Investigating infection risk and the microbiome in blood cancer patients treated with CD19 CAR-T therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13241761·No longer recruiting·A trial looking at the effectiveness of a treatment made from donated stool samples to see if gut bacteria can be increased in patients having a transplant for blood cancer.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17655532·No longer recruiting·Personalised prehabilitation in acute myeloid leukaemia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10369994·No longer recruiting·A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of MTL-CEBPA in children with mucopolysaccharidosis type IH
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17160440·No longer recruiting·A randomised controlled trial to assess the safety and effectiveness of stem cell transplantation using a reduced intensity regimen in patients with treatment resistant Crohn’s disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11966493·No longer recruiting·Post haematopoietic stem cell transplant follow-up
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74928896·No longer recruiting·CytoMegaloVirus~IMmunoProphylactic Adoptive Cellular Therapy study
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Complications after hematopoietic stem cell transplantation — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Complications after hematopoietic stem cell transplantation" OR "Complications after HSCT"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Complications after hematopoietic stem cell transplantation" OR "Complications after HSCT"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-27T03:32:42.153Z
